Patents by Inventor John Messenheimer
John Messenheimer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148669Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.Type: ApplicationFiled: October 6, 2023Publication date: May 9, 2024Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Nancy Tich, John Messenheimer, Donna Gutterman, Daniel Clauw, Ted Smith, James Griesser
-
Publication number: 20230414533Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: ApplicationFiled: August 30, 2023Publication date: December 28, 2023Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
-
Patent number: 11779549Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: GrantFiled: August 24, 2022Date of Patent: October 10, 2023Assignee: ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
-
Publication number: 20230000790Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: ApplicationFiled: August 24, 2022Publication date: January 5, 2023Applicants: ZYNERBA PHARMACEUTICALS, INC., ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
-
Patent number: 11458110Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: GrantFiled: August 6, 2020Date of Patent: October 4, 2022Assignee: ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
-
Publication number: 20220218625Abstract: The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.Type: ApplicationFiled: March 17, 2022Publication date: July 14, 2022Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Terri Sebree, Donna Gutterman, John Messenheimer
-
Publication number: 20210077421Abstract: The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.Type: ApplicationFiled: September 16, 2020Publication date: March 18, 2021Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Terri Sebree, John Messenheimer, Donna Gutterman
-
Publication number: 20210030665Abstract: The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.Type: ApplicationFiled: August 18, 2020Publication date: February 4, 2021Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Donna Gutterman, Terri Sebree, Ted Smith, John Messenheimer
-
Publication number: 20200360299Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: ApplicationFiled: August 6, 2020Publication date: November 19, 2020Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
-
Patent number: 10758497Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: GrantFiled: October 7, 2019Date of Patent: September 1, 2020Assignee: ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
-
Publication number: 20200170963Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.Type: ApplicationFiled: February 12, 2020Publication date: June 4, 2020Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Nancy Tich, John Messenheimer, Donna Gutterman, Daniel Clauw
-
Publication number: 20200030255Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: ApplicationFiled: October 7, 2019Publication date: January 30, 2020Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
-
Patent number: 10471022Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: GrantFiled: January 16, 2019Date of Patent: November 12, 2019Assignee: ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
-
Publication number: 20190167605Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: ApplicationFiled: January 16, 2019Publication date: June 6, 2019Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
-
Publication number: 20190083388Abstract: The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.Type: ApplicationFiled: September 18, 2018Publication date: March 21, 2019Applicant: ZYNERBA PHARMACEUTICALS, INC.Inventors: Donna Gutterman, Terri Sebree, Theodore Smith, John Messenheimer
-
Patent number: 10213390Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.Type: GrantFiled: September 27, 2018Date of Patent: February 26, 2019Assignee: ZYNERBA PHARMACEUTICALS, INC.Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree